Overview

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

Status:
Active, not recruiting

Trial end date:
2022-11-18

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or without metformin.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Insulin
Insulin Glargine
Insulin Lispro
Insulin, Globin Zinc
LY3298176
Tirzepatide